![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, February 10, 2011 3:49:23 PM
NewCardio, Inc., a cardiovascular diagnostic solutions developer, announced today that the Company has been invited to present the results of a key QTinno(R) performance study at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics (ASCPT), to be held in Dallas, March 3-5, 2011.
The study, entitled "Intelligent Automated ECG Extraction from Continuous 12-Lead Holter Recordings Reduces Measurement Variability in Thorough QT Studies," was completed in collaboration with physician scientists from a global pharmaceutical partner. Continuous 24-hour ECG recordings (Holters) are commonly used in cardiac safety drug studies. At present, the user visually selects three 10 second ECGs from the recording within 5 minutes of each designated study time point, a labor-intensive approach that is prone to error and variability. NewCardio has developed a novel ECG selection algorithm that evaluates the entire 10-minute window around the designated time point and selects the lowest noise and most stable ECGs in the window. The study chosen for presentation at the ASCPT meeting shows NewCardio's automated ECG selection method yields substantially more accurate and precise data than visual ECG selection. Moreover, the accuracy gain from automated ECG selection is fully additive to the accuracy gain delivered by QTinno itself.
Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "We are pleased to have this opportunity to present our results on automated ECG selection at the annual ASCPT meeting. This is a prestigious and well-attended forum, and gives us an excellent opportunity to share our latest QTinno improvements and innovations with scientists and professionals from academia, drug regulatory bodies, clinical trial service providers, and the pharmaceutical industry. The data we will be presenting demonstrate that NewCardio's novel automated ECG selection algorithm substantially improves data quality in drug safety studies. Pharma sponsors can use our automated ECG selection technology and QTinno to increase study power, thereby reducing the risk of a failed study. Alternatively, the sponsor can reduce the number of subjects in a study without sacrificing study power, which may represent a substantial cost savings. We believe this is a powerful extension of our platform technology, and demonstrates NewCardio's ability to add value to every ECG."
About QTinno Technology
NewCardio's patented QTinno 3-D ECG software technology is a novel, fully automated program for evaluating QT and other timing intervals relevant for assessing drug cardiac toxicity in drug development. It provides fast, accurate and precise QT data from a broad range of challenging ECGs and enables reliable, automated identification of key cardiac events. Pharmaceutical sponsors and clinical research organizations, which are mandated by the FDA to test new drugs for potential cardiac toxicity, are expected to benefit from QTinno's faster, more accurate and less expensive assessment of cardiac status.
About the American Society for Clinical Pharmacology and Therapeutics (ASCPT)
The American Society for Clinical Pharmacology and Therapeutics (ASCPT) consists of over 2,100 professionals committed to promoting and advancing the science and practice of human pharmacology and therapeutics, and is the largest professional organization serving the discipline of clinical pharmacology.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM